NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
Clinical Trials
18 trialsNCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT02966548 2025-02-17
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT06274437 2024-08-07
A Study of BND-35 in Participants With Advanced Solid Tumors
Biond Biologics
Phase 1 Recruiting
NCT03525925 2024-03-18
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02467361 2023-11-14
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Recruiting
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT02534506 2020-05-18
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01629758 2015-03-06
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed